Journal article
Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate
AC Phillips, ER Boghaert, KS Vaidya, HD Falls, MJ Mitten, PJ DeVries, L Benatuil, CM Hsieh, JA Meulbroek, SC Panchal, FG Buchanan, KR Durbin, MJ Voorbach, DR Reuter, SR Mudd, LI Loberg, SL Ralston, D Cao, HK Gan, AM Scott Show all
Molecular Cancer Therapeutics | AMER ASSOC CANCER RESEARCH | Published : 2018
Abstract
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glioblastoma multiforme (GBM) patients and is currently being evaluated in clinical trials in first-line and recurrent GBM disease settings. Depatux-m responses have been restricted to patients with amplified EGFR, highlighting the need for therapies with activity against tumors with nonamplified EGFR overexpression. In addition, depatux-m dosing has been limited by corneal side effects common to MMAF conjugates. We hypothesized that a monomethyl aur..
View full abstractGrants
Funding Acknowledgements
The design, conduct, and financial support for the study were provided by AbbVie.